Methods and pharmaceutical compositions for preventing and treating renal impairment
The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A 1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent. The invention further encompasses pharmaceutical compositions comprising an A 1 adenosine receptor antagonist alone or with, at least, one additional therapeutic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing renal impairment.
1. A method of increasing creatinine clearance at a low fractional excretion of sodium in a subject, the method consisting of administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting of an A 1 adenosine receptor antagonist alone as a therapeutic agent, in combination with a pharmaceutically acceptable carrier, wherein the A 1 adenosine receptor antagonist is 3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-[ethyl-(2-hydroxyethyl)-amino]-ethyl}-1-propyl-3,7-dihydropurine-2,6-dione.